Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, p<scp>lacebo‐controlled</scp> study (<scp>IRON</scp>‐<scp>CLAD</scp>)
Tamta Makharadze(Batumi Shota Rustaveli State University), Jeffrey A. Gilreath(University of Utah), Nicole Blackman(GlaxoSmithKline (United States)), Anna Julia Krupa(St. John's University), David H. Henry(Pennsylvania Hospital), Ralph V. Boccia(Center for Cancer and Blood Disorders)
Cited by 20
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
|European Journal of Cancer|2012|588
Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C
|New England Journal of Medicine|2007|451
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425